| Literature DB >> 31483915 |
Milan Obradovic1, Magbubah Essack2, Sonja Zafirovic1, Emina Sudar-Milovanovic1, Vladan P Bajic1, Christophe Van Neste2, Andreja Trpkovic1, Julijana Stanimirovic1, Vladimir B Bajic2, Esma R Isenovic1.
Abstract
Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology.Entities:
Keywords: cardiovascular diseases; cardiovascular system; reactive oxygen species; redox
Year: 2019 PMID: 31483915 PMCID: PMC7187163 DOI: 10.1002/biof.1559
Source DB: PubMed Journal: Biofactors ISSN: 0951-6433 Impact factor: 6.113
Figure 1Effects of ROS in physiological and pathophysiological conditions
Some ROS species important for vascular physiology and pathophysiology
| ROS | Mechanism of generation/enzymatic source | Physiological concentrations | Reference | Elevated concentrations | Reference |
|---|---|---|---|---|---|
| •O2 |
The electron transport chain of mitochondria |
EC growth, proliferation, survival, and angiogenesis |
|
Enhanced vasoconstriction Impaired vasorelaxation Decreased sGC activity/expression Vascular remodeling Sympathetic activation Endothelial dysfunction Peripheral resistance DNA damage EC apoptosis VSMC hypertrophy VSMC matrix regulation Hypertensions Atherosclerosis |
|
|
Monooxygenase |
Contraction–relaxation | ||||
|
NADPH oxidase |
Maintaining cardiac and vascular integrity |
| |||
|
Xanthine oxidase Lipooxygenase eNOS uncoupling |
| ||||
| H2O2 |
From •O2 by SOD |
EC growth, proliferation, survival, and angiogenesis Endothelium‐dependent vasorelaxation Cytoskeletal reorganization of EC Inflammatory responses of EC Endothelium‐regulated vascular remodeling Vasodilation Synthesis/release of endothelium‐derived relaxing factor |
|
Impaired proliferation and/or decreased viability of EC EC apoptosis VSMC hypertrophy VSMC proliferation VSMC matrix regulation VSMC apoptosis Vascular relaxation and hyperpolarization Hypertension Atherosclerosis |
|
|
Directly produced by: |
| ||||
|
Glucose oxidase |
| ||||
|
Xanthine oxidase |
| ||||
|
‐NADPH oxidase 4 isoform |
| ||||
|
| |||||
|
| |||||
| •OH |
Produced in Haber–Weiss reaction from •O2 and H2O2 from reactions with hypochlorous acid |
Vasodilation VSMC relaxation Synthesis/release of endothelium‐derived relaxing |
|
Atherosclerosis Lipid peroxidation |
|
| ONOO− |
Produced in reaction of NO and •O2 |
Regulation of vascular contraction/relaxation Trigger stress adaptation Protection of vascular endothelium |
|
Impairment of vascular relaxation by various mechanisms EC and VSMC apoptosis Peripheral vascular failure Lipid peroxidation Oxidation of BH4 Oxidation of sGC Oxidative DNA damage Endothelial dysfunction |
|
Note: Under physiological conditions, ROS in the vasculature are produced in a controlled manner at low concentrations and function as signaling molecules. Increased ROS production leads to pathological conditions of vascular system.
Abbreviations: •OH, hydroxyl radical; BH4, tetrahydrobiopterin; EC, endothelial cell; eNOS, endothelial nitric oxide synthase; H2O2, hydrogen peroxide; NADPH, nicotinamide adenine dinucleotide phosphate; NO, nitric oxide; O2, superoxide anion; ONOO−, peroxynitrite; sGC, soluble guanylate cyclase; SOD, superoxide dismutase; VSMC, vascular smooth muscle cells.
The effects of ROS on vascular physiology‐ animal and human studies
| Effects of ROS | Condition and/or treatment | Species | Ref. | ||
|---|---|---|---|---|---|
|
Endothelial dysfunction |
↑ OxS ↑ XO activity |
Ang II‐induced vascular dysfunction |
dTGR SDR |
| |
|
↑ Arteriolar tone | ↑ XO activity | SHR |
| ||
|
Correct hypertrophy of renal and cardiac tissue | ↑ XO activity |
Allopurinol Sodium restriction |
SHR DSS rats |
| |
|
↑ Systolic blood pressure Endothelial dysfunction Vascular hypertrophy |
↑ O2 − ↑ p22phox mRNA |
Irbesartan |
SHR WKY |
| |
|
Atherosclerosis | ↑ ROS |
Ang II‐mediated MAP kinase activation | Rat VSMC |
| |
|
↑ Systolic blood pressure | ↑ O2 − |
Ang II‐induced hypertension |
| ||
|
Stimulate vascular smooth muscle cell growth |
↑H2O2 ↑O2 − |
Naphthoquinolinedione LY83583 |
| ||
|
↓ Expression of proinflammatory molecules | ↑ O2 − |
Angiotensin receptor inhibition gp91phox NAD(P)H oxidase inhibiton |
Hypertensive DSS rat |
| |
|
↓ Vascular superoxide production |
↑ superoxide production ↑ ET‐1 |
ETA receptor inhibition | DOCA‐salt hypertensive mice and rats |
| |
|
Attenuated blood pressure elevation | ↑ O2 − |
Ang II–induced hypertension Inhibited association of p47 |
Mice/ Aortic rings |
| |
|
↑ Mean blood pressure Nox1(+/Y) ↓ Production of superoxide in Nox1(−/Y) Preserved endothelium‐dependent relaxation in Nox1(−/Y) | ↑ ROS |
Ang II‐induced hypertension |
Nox1‐deficient (−/Y) mice |
| |
|
↑ Systolic blood pressure ↑ Aortic hypertrophy Development of cardiovascular pathologies | ↑ superoxide production | VSMC TgSMCnox1 |
| ||
|
No changes in blood pressure of p47phox−/−deficient mice after Ang II tratment | ↑ O2 − | p47phox−/−deficient mice |
| ||
|
↓ Aneurysm formation ↓ NO | ↑ ROS |
NADPH oxidase inhibition | iNOS−/− mice |
| |
|
Dysfunction of the endothelium Vascular remodeling | ‐ |
ET‐1 overexpression |
C57BL/6 TG and WT mice |
| |
|
↓ NO levels | ↑ O2 − production |
PMA stimulation | Hypertensive and normotensive patients |
| |
|
↑Oxidized/reduced glutathione ratio ↓ Activity of superoxide dismutase, catalase, and glutathione peroxidase Development of cardiovascular complications | ↑ ROS | ‐ | Hypertensive and normotensive patients |
| |
Abbreviations: ↑, increased; ↓ decreased; Ang II, angiotensin II; DOCA, salt‐deoxycorticosterone acetate‐salt; DSS, Dahl salt‐sensitive; dTGR, double‐transgenic rats; ET‐1, endothelin‐1; iNOS−/−, iNOS‐deficient; ONOO−, peroxynitrite; OxS, oxidative stress; PMA, phorbol myristate acetate; SDR, Sprague Dawley rats; SHR, spontaneously hypertensive rats; TG, transgenic; TgSMCnox1, transgenic mice overexpressing Nox1 in smooth muscle cells; VSMC, vascular smooth muscle cell; WKY, Wistar‐Kyoto rats; WT, wild type (nontransgenic); XO, xanthine oxidase.
Figure 2Chemical substances connecting vascular smooth muscle cells (VSMC) and gene ontology (GO) biological functions. Chemical substances from ChEBI are shown with a blue background color and GO biological functions with yellow color. The transparency of the edge indicates the frequency of co‐occurrence of the connected terms. The graph was formed by extracting all ChEBI or GO term co‐occurrences with “vascular associated smooth muscle cell” from the DES‐RedoxVasc KB. The connection between CheBI and GO terms already extracted in the first step was also added. A general filter was applied to the edges to have at least two articles reporting co‐occurrence. The layout of the graph was first force‐directed by the amount of co‐occurrence between two terms, but then manually adjusted for readability of the nodes
Figure 3DES‐RedoxVasc network illustrating microRNAs that may affect the relationship among “VASCULAR ENDOTHELIAL CELL”, “Oxidative stress response”, and “Polyunsaturated Fatty Acids.” The orange circles denote concepts from the “human microRNAs” dictionary; the green circles denote concepts from the “HFO Ontology (Bioportal) Heart Failure Ontology” dictionary; the blue circles denote concepts from the “Pathways (KEGG, Reactome, UniPathway, Panter)” dictionary; and the red circles denote concepts from the “Human Anatomy” dictionary